Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas F Stoop

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Annals of Surgery|September 17, 2024
Poor Prognostic Factors in Long-Term Survivors of Resected Pancreatic Ductal Adenocarcinoma: An International, Multicenter Cohort StudyAmmar A Javed, Ingmar F Rompen, Iris W J M van Goor, et al.
Annals of Surgery|August 12, 2025
Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled TrialEsther N Dekker, Rutger T Theijse, Jacob L van Dam, et al.
BJS Open|June 9, 2026
Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including arterial divestment or arterial resectionThomas F Stoop, Freek R van 't Land, Leonard W F Seelen, et al.
Annals of Surgery|January 31, 2025
Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOXIngmar F Rompen, Thomas F Stoop, Stijn van Roessel, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|May 21, 2026
Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation of prognostic modelsAmmar A Javed, Mahsoem Ali, Omar Mahmud, et al.
Journal of the National Cancer Institute|September 3, 2025
Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinomaAmmar A Javed, Asad Saulat Fatimi, Ingmar F Rompen, et al.
British Journal of Cancer|May 6, 2025
Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an international multicentre studyThomas F Stoop, Y H Andrew Wu, Atsushi Oba, et al.
JAMA Oncology|January 23, 2025
Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOXThomas F Stoop, Toshitaka Sugawara, Atsushi Oba, et al.
Annals of Surgery|August 6, 2021
The Impact of Neoadjuvant Treatment on Survival in Patients Undergoing Pancreatoduodenectomy With Concomitant Portomesenteric Venous Resection: An International Multicenter AnalysisNikolaos Machairas, Dimitri A Raptis, Patricia Sánchez Velázquez, et al.
The British Journal of Surgery|June 22, 2026
Surgical Outcomes from Nationwide Implementation of the International Best-Practice for Locally Advanced Pancreatic Cancer (PREOPANC-4) studyThomas F Stoop, Leonard W F Seelen, Freek R van 't Land, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Annals of Surgery|September 17, 2024
Poor Prognostic Factors in Long-Term Survivors of Resected Pancreatic Ductal Adenocarcinoma: An International, Multicenter Cohort StudyAmmar A Javed, Ingmar F Rompen, Iris W J M van Goor, et al.
Annals of Surgery|August 12, 2025
Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled TrialEsther N Dekker, Rutger T Theijse, Jacob L van Dam, et al.
BJS Open|June 9, 2026
Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including arterial divestment or arterial resectionThomas F Stoop, Freek R van 't Land, Leonard W F Seelen, et al.
Annals of Surgery|January 31, 2025
Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOXIngmar F Rompen, Thomas F Stoop, Stijn van Roessel, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|May 21, 2026
Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation of prognostic modelsAmmar A Javed, Mahsoem Ali, Omar Mahmud, et al.
Journal of the National Cancer Institute|September 3, 2025
Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinomaAmmar A Javed, Asad Saulat Fatimi, Ingmar F Rompen, et al.
British Journal of Cancer|May 6, 2025
Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an international multicentre studyThomas F Stoop, Y H Andrew Wu, Atsushi Oba, et al.
JAMA Oncology|January 23, 2025
Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOXThomas F Stoop, Toshitaka Sugawara, Atsushi Oba, et al.
Annals of Surgery|August 6, 2021
The Impact of Neoadjuvant Treatment on Survival in Patients Undergoing Pancreatoduodenectomy With Concomitant Portomesenteric Venous Resection: An International Multicenter AnalysisNikolaos Machairas, Dimitri A Raptis, Patricia Sánchez Velázquez, et al.
The British Journal of Surgery|June 22, 2026
Surgical Outcomes from Nationwide Implementation of the International Best-Practice for Locally Advanced Pancreatic Cancer (PREOPANC-4) studyThomas F Stoop, Leonard W F Seelen, Freek R van 't Land, et al.
Pageof 7